An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Waters Corporation (NYSE:WAT) has acquired technology assets and intellectual property from Megadalton Solutions, enhancing its capabilities in Charge Detection Mass Spectrometry (CDMS). This acquisition allows Waters to overcome the limitations of traditional mass spectrometry, particularly in analyzing large proteins used in cell and gene therapies. The integration of CDMS technology is expected to expand Waters' product offerings and attract new customers in the biopharmaceutical sector, potentially boosting revenue from next-generation biologics.
Positive
Acquisition of CDMS technology enhances Waters' mass spectrometry portfolio.
Addresses challenges in analyzing large proteins for cell and gene therapies.
Potential to attract new customers in the biopharmaceutical sector.
Negative
None.
News Summary:
Waters has acquired technology assets and intellectual property rights of Megadalton Solutions, an early-stage developer of charge detection mass spectrometry (CDMS).
CDMS overcomes limitations of conventional mass spectrometry in characterizing complex large molecules in cell and gene therapies.
CDMS technology will be further developed to extend capabilities of Waters’ mass spectrometry portfolio for broader set of applications and potential customers.
MILFORD, Mass.--(BUSINESS WIRE)--
Waters Corporation (NYSE:WAT) today announced it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass Spectrometry (CDMS) technology and services. Financial details of the transaction are not being disclosed.
Founded in 2018 by professors Martin Jarrold and David Clemmer at Indiana University, Megadalton Solutions has developed CDMS instrumentation that makes it possible to analyze extremely large proteins and protein complexes, such as those used in cell and gene therapies, that would otherwise be difficult to analyze with conventional mass spectrometry. Waters became a strategic investor in the company and in 2021 brought Megadalton’s CDMS technology into the Waters Immerse™ Cambridge innovation and research lab for advanced testing and development.
“Large molecule mass spectrometry with CDMS offers an important tool for the characterization, analysis and quantification of next-generation biologics, such as cell and gene therapies, which is an area of high interest among biopharmaceutical and biomedical research customers,” said Dr. Udit Batra, President and CEO, Waters Corporation. “Large molecules can be extremely challenging to characterize with conventional mass spectrometry because of their complexity. We are looking forward to further developing and commercializing the Megadalton CDMS technology to help customers analyze and quantify large molecules in applications such as cell and gene therapy drug development.”
“We developed our CDMS detector to bring the precision of mass spectrometry to the analysis of complex biologics,” said Dr. Martin Jarrold, CEO of Megadalton Solutions, Inc. “It is an exciting milestone in our journey to have Waters carry forward and continue the development of CDMS for the analysis of large molecules such as gene-based therapies that represent the next generation of medicine.”
Waters Corporation(NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Kevin Kempskie Corporate Communications
Waters Corporation PR@waters.com
Source: Waters Corporation
FAQ
What did Waters Corporation acquire from Megadalton Solutions?
Waters Corporation acquired technology assets and intellectual property rights related to Charge Detection Mass Spectrometry (CDMS) from Megadalton Solutions.
How will the CDMS technology impact Waters Corporation's business?
The CDMS technology will enhance Waters' mass spectrometry capabilities, enabling better analysis of large proteins and potentially increasing its market share in the biopharmaceutical sector.
When was the acquisition of Megadalton Solutions announced?
The acquisition was announced on February 1, 2022.
What is the significance of CDMS technology for cell and gene therapies?
CDMS technology allows for the precise analysis of large proteins, which is critical for the development of next-generation biologics like cell and gene therapies.
What benefits does the acquisition of Megadalton Solutions provide for Waters Corporation's customers?
Customers will benefit from improved analysis and quantification of large molecules in drug development applications, enhancing their research capabilities.
